Key result
The 2023 AHA/ACC multisociety guideline on chronic coronary disease provides updated guidance on pharmacotherapy, symptom relief, and prevention of cardiovascular events.
The 2023 AHA/ACC guideline on chronic coronary disease introduces new standards for evidence-based cardiovascular care, with notable differences in pharmacotherapy compared to the 2019 ESC guidelines.
The 2023 American Heart Association ( AHA ) /American College of Cardiology ( ACC ) multisociety guideline on chronic coronary disease ( CCD ) 1 was recently released to provide updated guidance to clinicians managing this heterogeneous, difficult-to-treat population. This guideline sets new standards for evidence-based cardiovascular care, and although it focuses on US practice, its relevance extends to patients worldwide. Important domains include therapeutic approaches for symptom relief, prevention of atherosclerosis-related cardiovascular events, and management of heart failure ( HF ) . In this editorial, we outline the main innovations and differences in pharmacotherapy in relation to the 2019 European Society of Cardiology ( ESC ) guidelines on chronic coronary syndromes 2 ( which are likely to diminish with the publication of the next iteration, scheduled for 2024 ) .
No takes yet. Share an insight, caveat, or question.
Gragnano et al. (2023) conducted an editorial in chronic coronary disease. 2023 AHA/ACC multisociety guideline vs. 2019 ESC guidelines was evaluated. The 2023 AHA/ACC multisociety guideline on chronic coronary disease provides updated guidance on pharmacotherapy, symptom relief, and prevention of cardiovascular events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: